[Fatal exacerbations of chronic active Epstein-Barr virus infection subsequent to cytotoxic chemotherapy].
Chronic active Epstein-Barr virus infection
Epstein-Barr virus
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis
Hemophagocytic syndrome flare
Journal
[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
17
8
2019
Statut:
ppublish
Résumé
Chronic active Epstein-Barr virus infection (CAEBV) is critical owing to lethal complications such as hemophagocytic lymphohistiocytosis (HLH), multiple organ failure, and malignant lymphoma. Here we present two cases of CAEBV who developed rapid and life-threatening disease progression after cytotoxic chemotherapy. Case 1: In a 34-year-old male, CAEBV recurred after 4-month remission obtained by initial therapy with etoposide, cyclosporine, and prednisolone. Accordingly, cord blood transplantation was planned. A day after administering high-dose melphalan as the conditioning, he developed respiratory failure, pancytopenia, and hyperferritinemia. He died 3 days later. Case 2: A 53-year-old female attained remission after initial therapy for CAEBV. After 1 month, she relapsed, and high-dose cytarabine (HDAC) was administered. A day after HDAC administration, she suddenly developed respiratory failure, which was followed by multiple organ failure. She died 3 days later. Thus, planned strategy for prompt allogeneic hematopoietic stem cell transplantation is necessary to prevent disease progression and control cytokinemia before cytotoxic chemotherapy for CAEBV.
Identifiants
pubmed: 31068557
doi: 10.11406/rinketsu.60.286
doi:
Types de publication
Case Reports
Journal Article
Langues
jpn